Health Care Resource Utilization and Costs among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France
Table 1
Patient and treatment characteristics.
Overall
United Kingdom
Spain
Germany
France
(%)
(%)
(%)
(%)
(%)
Total patients
807
100
199
100
203
100
204
100
201
100
Sex
Male
475
58.9
126
63.3
123
60.6
130
63.7
96
47.8
Female
332
41.1
73
36.7
80
39.4
74
36.3
105
52.2
Ethnicitya
White/Caucasian
562
92.7
178
89.5
201
99.0
183
89.7
—
—
African/black
14
2.3
10
5.0
0
0
4
2.0
—
—
Asian or Pacific Islander
14
2.3
6
3.0
0
0
8
3.9
—
—
Middle Eastern
8
1.3
2
1.0
2
1.0
4
2.0
—
—
Indian subcontinent
8
1.3
3
1.5
0
0
5
2.5
—
—
Age at advanced diagnosis
Mean (SD)
57.1
12.3
56.5
12.4
56.6
13.1
57.4
11.0
57.9
12.6
Range (min, max)
21
90
21
90
21
85
28
77
22
84
Histological category
Leiomyosarcoma
229
28.4
61
30.7
45
22.2
66
32.4
57
28.4
Others/NOS
183
22.7
40
20.1
35
17.2
43
21.1
65
32.3
Fibroblastic/myofibroblastic
78
9.7
24
12.1
18
8.9
20
9.8
16
8.0
Liposarcoma
105
13.0
14
7.0
44
21.7
22
10.8
25
12.4
Vascular sarcoma
79
9.8
16
8.0
25
12.3
17
8.3
21
10.4
Rhabdomyosarcoma
86
10.7
33
16.6
20
9.9
21
10.3
12
6.0
Synovial sarcoma
47
5.8
11
5.5
16
7.9
15
7.4
5
2.5
Total number of lines of therapy received
Mean (SD)
1.6
0.8
1.4
0.6
1.6
0.8
1.47
0.6
1.9
1.0
Distribution
1
456
56.5
124
62.3
117
57.6
122
59.8
93
46.3
2
262
32.5
64
32.2
66
32.5
70
34.3
62
30.9
3+
89
11.0
11
5.5
20
9.9
12
5.9
46
22.9
NOS = not otherwise specified; SD = standard deviation. aNot collected in France.
